KAKKIS EMIL D (President & CEO) sold 13.3% of their position (98.43K shares) of ULTRAGENYX PHARMACEUTICAL INC. on the open market
Open‑market sale worth $4.15M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 3/4/2025ACC: 0000950170-25-032779
DirectorOfficer· President & CEO
Since Mar 2026
+130.57K
Net shares
Net buyer
$4.15M
Total sold
2
Open market trades
0B · 2S
5
Total transactions
229.01K acquired · 98.43K disposed
Non-Derivative Transactions4
Common Stock
Indirect
Shares
−25K
Price / share
$42.48
Trade value
$1.06M
% of position
1.1%
2/28/2025
2.18M→2.16M
Common Stock
Direct
Shares
+43.27K
Price / share
—
Trade value
—
% of position
7.7%
3/1/2025
564.61K→607.87K
Common Stock
Direct
Shares
+107.29K
Price / share
—
Trade value
—
% of position
17.7%
3/1/2025
607.87K→715.16K
Common Stock
Direct
Shares
−73.43K
Price / share
$42.10
Trade value
$3.09M
% of position
10.3%
3/3/2025
715.16K→641.73K
Total
Net shares
+52.13K
Net value
-$4.15M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 2/28/2025 | S · Sale | −25K | $42.48 | $1.06M | 1.1% | 2.18M | 2.16M |
| Common Stock Direct | 3/1/2025 | A · Award | +43.27K | — | — | 7.7% | 564.61K | 607.87K |
| Common Stock Direct | 3/1/2025 | A · Award | +107.29K | — | — | 17.7% | 607.87K | 715.16K |
| Common Stock Direct | 3/3/2025 | S · Sale | −73.43K | $42.10 | $3.09M | 10.3% | 715.16K | 641.73K |
| Total | +52.13K | -$4.15M | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
78.45K shares
Shares
+78.45K
Strike price
42.92
Held after
78.45K
Exercisable
—
3/1/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock78.45K shares | 3/1/2025 | A · Award | +78.45K | 42.92 | — | 78.45K |